XULTOPHY 100 UNIT-3.6 MG/ML PEN

What it is

XULTOPHY 100 UNIT-3.6 MG/ML PEN is how the CMS NADAC file names this product. The FDA NDC Directory lists it as insulin degludec and liraglutide, under the trade name “Xultophy 100/3.6”.

FDA gives its dosage form as injection, solution and its route as subcutaneous.

The labeler, the company named on the label, is Novo Nordisk.

FDA lists it under 2 Established Pharmacologic Classes: GLP-1 Receptor Agonist and Insulin Analog.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00169-2911-15.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $1,288.28 for 15 mL (15 × $85.88557 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

What NADAC measures · NADAC explanation codes

The NDC

• 00169-2911-15 · Novo Nordisk · $85.88557 per ML · eff. 2026-09-23 filed

Compared with its class

Its NADAC price is $85.88557 per ML filed.

Of the 39 other products in FDA’s GLP-1 Receptor Agonist class priced per ML, 35 have a higher middle NADAC price and 4 a lower one. The one in the middle is WEGOVY 1.7 MG/0.75 ML PEN, at $435.55769 per ML filed (eff. 2026-09-23).

Of the 56 other products in FDA’s Insulin Analog class priced per ML, 2 have a higher middle NADAC price and 54 a lower one. The one in the middle is TRESIBA FLEXTOUCH 100 UNIT/ML, at $9.03577 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $1,223.50 for 15 mL, at an average of $81.56641 per ML in 2024 (2024-01-01 to 2024-12-31) for “Xultophy 100-3.6” and “Insulin Degludec/Liraglutide”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 57,197 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 15 mL? Is it lower than what I would pay through my insurance?
• How much is in the package I am getting? This page uses 15 mL; your package may hold a different amount.
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.